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OBJECTIVE—Two type 1 diabetes susceptibility genes have
been identiﬁed in the spontaneously diabetic biobreeding diabe-
tes-prone (BBDP) rat, the major histocompatibility complex
(MHC) (RT1) class II u haplotype (Iddm1) and Gimap5 (Iddm2).
The strong effects of these have impeded previous efforts to map
additional loci. We tested the hypothesis that type 1 diabetes is a
polygenic disease in the BBDP rat.
RESEARCH DESIGN AND METHODS—We performed the
most comprehensive genome-wide linkage analysis for type 1
diabetes, age of disease onset (AOO), and insulitis subpheno-
types in 574 F2 animals from a cross-intercross between BBDP
and type 1 diabetes–resistant, double congenic ACI.BBDP-
RT1u,Gimap5 (ACI.BB
1u.lyp) rats, where both Iddm1 and Iddm2
were ﬁxed as BBDP.
RESULTS—A total of 19% of these F2 animals developed type 1
diabetes, and eight type 1 diabetes susceptibility loci were
mapped, six showing signiﬁcant linkage (chromosomes 1, 3, 6
[two loci], 12, and 14) and two (chromosomes 2 and 17)
suggestive linkage. The chromosomes 6, 12, and 14 intervals were
also linked to the severity of islet inﬁltration by immunocytes,
while those on chromosomes 1, 6 (two loci), 14, 17, and a type 1
diabetes–unlinked chromosome 8 interval showed signiﬁcant
linkage to the degree of islet atrophy. Four loci exhibited
suggestive linkage to AOO on chromosomes 2 (two loci), 7, and
18 but were unlinked to type 1 diabetes. INS, PTPN22, IL2/IL21,
C1QTNF6, and C12orf30, associated with human type 1 diabe-
tes, are contained within the chromosomes 1, 2, 7, and 12 loci.
CONCLUSIONS—This study demonstrates that the BBDP dia-
betic syndrome is a complex, polygenic disease that may share
additional susceptibility genes besides MHC class II with human
type 1 diabetes. Diabetes 58:1007–1017, 2009
T
he biobreeding diabetes-prone (BBDP) rat spon-
taneously develops type 1 diabetes with high
incidence around puberty through a T-cell–me-
diated autoimmune destruction of pancreatic
-cells (1). Two genes that contribute to disease pathogen-
esis in this animal have been identiﬁed, the RT1u allele
(Iddm1) and the GTPase immunity-associated protein fam-
ily member 5 (Gimap5, Iddm2) (2–4). Genetic variation in
Gimap5 has been recently associated with humoral anti-
pancreatic autoimmunity in human type 1 diabetes as well
as with human systemic lupus erythematosus (5,6).
Crosses between BBDP rats and type 1 diabetes–resistant
strains have shown that homozygosity for the BBDP
Gimap5 allele and at least one BBDP allele of Iddm1 are
required for type 1 diabetes development (4,7). These
requirements have impeded previous efforts to map addi-
tional Iddm loci. However, in an attempt to circumvent
these difﬁculties, two experimental approaches have been
used.
First, linkage analyses have been performed in progeny
derived from backcrosses (F1N2 or F2N3) between BBDP
and type 1 diabetes–resistant strains, speciﬁcally designed
to enrich for BBDP homozygosity at both Iddm1 and
Iddm2. This approach led to the identiﬁcation of Iddm3
(chromosome 2) in one study, while in others more than
one locus was mapped, but they met only suggestive
genome-wide statistical criteria (8–12). However, the de-
sign of these crosses had two disadvantages. They could
not be used to investigate the effects of homozygosity for
non-BBDP alleles since they were backcrosses to BBDP.
Furthermore, as Iddm1 and Iddm2 were selected to be
homozygous, loci in close proximity to them could be
missed, as was likely the case for a locus close to Iddm2
(8,13–15).
The second approach examined the genetics of experi-
mentally induced (as opposed to spontaneous) diabetic
syndromes following the demonstration that many rat
strains carrying the BBDP allele at Iddm1 were highly
susceptible to these syndromes (16). This approach had
the advantage of eliminating the requirement for BBDP
homozygosity at Iddm2, thus increasing the number of
informative progeny in crosses. However, only one locus
(other than Iddm1) identiﬁed by this approach, Iddm14,
has been shown to also control spontaneous type 1
diabetes (15). The results of these two approaches
strongly suggested that contrary to spontaneous diabetes
in humans and nonobese diabetic (NOD) mice, which are
both under the control of multiple genes (17–19), type 1
diabetes in the BBDP rat was oligogenic with one or two
susceptibility genes other than Iddm1 and 2 depending on
the resistant strain used (8,9,12,13).
To determine whether this is the case, we have taken a
different approach that overcomes some of the limitations
encountered in previous studies. First, we introgressed
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DIABETES, VOL. 58, APRIL 2009 1007BBDP-derived Iddm1 and Iddm2 onto the genetic back-
ground of the diabetes-resistant August Copenhagen Irish
(ACI) inbred strain. The resulting double congenic
ACI.BBDP-RT1
u,Gimap5 (ACI.BB
1u.lyp) inbred strain ex-
hibits complete resistance to both spontaneous type 1
diabetes and islet inﬂammation (20), establishing the re-
quirement for at least one other susceptibility locus and
allowing us to test the hypothesis that the BBDP diabetic
syndrome is also under complex, polygenic control. Spe-
ciﬁcally, this congenic line allowed us to ﬁx both Iddm1
and Iddm2 loci as BBDP in a cross/intercross with the
BBDP strain. Here, using this F2 cohort, we report the
results of the most comprehensive genome-wide linkage
analysis performed in the BBDP rat.
RESEARCH DESIGN AND METHODS
The genetic analysis consisted of a three-step approach. In the ﬁrst step,
diabetic animals were genotyped across the genome using 229 microsatellite
markers at an average of one marker every 12.5 Mb (maximal distance
between two markers was 28.7 Mb). Information on the primers and their
physical location was obtained from the Rat Genome Database (available at
http://rgd.mcw.edu/) and is listed in supplementary Table 1 (available at
http://dx.doi.org/10.2337/db08-1215). This was followed by segregation analy-
sis of type 1 diabetes based on the comparison of the observed to the expected
genotype distribution at each marker. In the second step, at each peak marker
linked to diabetes with a log10 likelihood ratio (logarithm of odds [LOD])
score 1 in the ﬁrst step, we genotyped all nondiabetic animals. Single-marker
analysis was then performed to check that the linkage was type 1 diabetes
speciﬁc as opposed to the consequence of an overall bias in Mendelian
inheritance. In the third step, markers ﬂanking those peaks linked to type 1
diabetes with a LOD 1.5 in step 2 were also genotyped in all nondiabetic
subjects to reﬁne each peak through interval mapping analysis (21). Further
reﬁnement of linkage peaks was obtained through genotyping of the whole F2
cohort with additional and newly designed markers.
Before linkage analysis, R/QTL (22) was used to identify genotyping errors
and to check the marker order by re-estimating the genetic map for each order
through calculating the LOD scores relative to the initial order. For QTL
mapping, single-marker and QTL  sex interaction analyses were performed
using R/QTL with a binary model used for type 1 diabetes and a normal model
for other traits. Segregation analysis, interval mapping (21), and composite
interval mapping were conducted using Windows QTL Cartographer, version
2.5 (23). For linkage analysis, we calculated LOD scores in both R/QTL and
QTL Cartographer using a full model, allowing for both additive and domi-
nance effects. LOD thresholds were determined by permutation testing (n 
1,000 permutations) (24). Suggestive loci were deﬁned as those that exceeded
the 37th percentile (P  0.63) of permutation distribution, while signiﬁcant
loci exceeded the 95th percentile (P  0.05). Power calculations showed that
for type 1 diabetes there was good power (1-0.8) to detect a relative risk
of 2.0 with 1  10
4, while for quantitative traits we could detect a locus
that contributes to 4% of the trait variance at 1  10
4. The loci identiﬁed
through the above analyses were designated Iddm25 to Iddm36 by the Rat
Genome Database and have been added to the list of previously mapped Iddm
loci at http://rgd.mcw.edu/, while details about these 12 loci are available at
http://www.t1dbase.org/page/welcome/display/?species  rat. Details of the
animals used and phenotypic analysis of the pancreas are provided in the
online appendix.
RESULTS
Of 470 F2 animals that remained negative for glycosuria
until 165 days, 23 were found postmortem to have glyce-
mia 16.7 mmol/l hence within the diabetic range on the
day of killing (25). However, they were excluded from our
analysis of cumulative incidence of type 1 diabetes and age
of onset (AOO) since we did not have glycemic levels on 2
consecutive days for them. Their pancreata were never-
theless included in the linkage analysis for insulitis. Of 551
F2 animals included for cumulative incidence of type 1
diabetes, 18.9% (n  104) became diabetic with an AOO of
(means  SD) 120  24 days compared with 84% at 76 
8 days in BBDP rats and 20.8% at 180  44 days in the F1
generation, respectively (Fig. 1A). There was a small, but
signiﬁcantly higher, cumulative incidence of type 1 diabe-
tes (P  0.048) in female F2 animals compared with males
(Fig. 1B). This led us to perform linkage analyses for type
1 diabetes, insulitis, and AOO separately in male and
female F2 animals. Based on permutation analyses using
R/QTL, signiﬁcant sex difference in linkage (LOD thresh-
old for QTL  sex interaction at 5% level 2.1) was found
only for type 1 diabetes at the telomeric locus of chromo-
some 6 (LOD  2.3). However, at this locus, although
female heterozygotes and ACI homozygotes had higher
type 1 diabetes incidence than males, BB homozygote
males had a signiﬁcantly higher incidence than BB
females.
Linkage analysis of type 1 diabetes. Through genome-
wide segregation analysis performed in diabetic animals
only, we identiﬁed six loci signiﬁcantly linked to type 1
diabetes on chromosomes 1, 3, 6 (two loci), 12, and 14 and
another suggestive linkage peak on chromosome 2 (Fig. 2).
Four of these regions are novel, on chromosomes 3, 6
(centromeric), 12, and 14, while three others overlap with
regions previously identiﬁed using alternative type 1 dia-
betes–resistant strains (8,9). When the genetic analysis
was extended to the whole F2 cohort, these peaks were all
conﬁrmed and an additional chromosome 17 locus reach-
ing suggestive linkage was found. Of note, some regions of
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FIG. 1. Analysis of type 1 diabetes–free survival in BBDP, F1 and F2 animals (A) and per gender in the F2 cohort (B). The percent survival of each
cohort is labeled on the vertical axis, and the number of days to onset of diabetes is labeled on the horizontal axis. A: Both the F1 and F2 cohorts
have signiﬁcantly increased type 1 diabetes–free survival rate compared with BBDP rats (P < 0.0001), whereas the F1 rate is not signiﬁcantly
different from that of the F2 cohort (Kaplan-Meier analysis log-rank statistic). B: Females have a lower (P  0.048) type 1 diabetes–free survival
rate compared with males.
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FIG. 2. Mapping of type 1 diabetes and type 1 diabetes subphenotypes in the F2 cohort along chromosomes 1–20. The Y-axis indicates the LOD score and the
X-axis the chromosome number and genetic position. Horizontal lines represent the thresholds for suggestive (dotted line) and signiﬁcant (dashed dotted
line) linkage. From the top to bottom are shown the results of linkage analyses for type 1 diabetes, severity of islet inﬁltration by inﬂammatory cells, degree
of islet integrity, and age of type 1 diabetes onset. Unless otherwise stated in the ﬁgure, all linkage analyses were based on interval mapping.
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lost when the whole cohort was genotyped.
BBDP type 1 diabetes susceptibility loci. At ﬁve of the
eight type 1 diabetes loci (chromosomes 2, 14, 17, and both
on 6), the BBDP allele conferred increased susceptibility
to the disease (Table 1). The peak of linkage (LOD  2.90;
Iddm26) on chromosome 2 is located at marker D2Arb16
(Table 1), and the 1-LOD interval spans 16 cM (supplemen-
tary Table 1 and supplementary Fig. 3A). The incidence of
type 1 diabetes in F2 animals that were BBDP homozygous
and heterozygous at the peak marker was 24 and 22%,
respectively, compared with 8% in ACI homozygous ani-
mals (Table 1). This locus overlaps with Iddm3, previ-
ously identiﬁed in a cross between DRlyp/lyp and F344
(8). Interestingly, the peak marker D2Arb16 is only 0.74
Mb away from Ptpn22 (199.05 Mb), a gene strongly
associated with both type 1 diabetes and other autoim-
mune diseases in humans (26–30) (Table 2).
Two type 1 diabetes loci were located close to each
other toward the telomere of chromosome 6 (Table 1,
supplementary Table 1, and supplementary Fig. 3B). The
more proximal locus (LOD  5.21; Iddm28) had a 1-LOD
interval of 20 cM between markers D6Rat23 and
D6Got169. The more distal locus is the most signiﬁcant
linkage in this cross (LOD  7.66; Iddm29), with a 1-LOD
interval spanning 10 cM between markers D6Mgh3 and
D6Got167. These two loci account for 4.5 and 6.3%,
respectively, of the trait variance in this cross. The distal
locus overlaps with Iddm8, previously identiﬁed in a
cross-backcross between the BB/OK and SHR/Mol strains,
subsequently conﬁrmed through the development of con-
genic strains (9). Using composite interval mapping, we
conﬁrmed that these two chromosome 6 QTLs are distinct
and we better deﬁned their peak location 30 cM apart
(supplementary Fig. 4).
Two other susceptibility loci on chromosomes 14 and 17
are also novel (supplementary Table 1 and supplementary
Figs. 3C and D). The former (LOD  4.7; Iddm31) has a
1-LOD interval spanning 12 cM between markers D14Rat1
and D14Mit6; however, this is possibly an underestimation
of the true locus size since the peak is at the most
centromeric marker along this chromosome. The latter
(LOD  1.98; Iddm36) has a 1-LOD interval of 30 cM.
BBDP type 1 diabetes resistance loci. There are three
loci where the BBDP allele confers resistance (or the ACI
allele confers susceptibility) to type 1 diabetes in this
cross (supplementary Table 1 and supplementary Figs.
5A–C). The strongest BBDP resistance locus (LOD  4.18;
Iddm25) maps to the telomere of chromosome 1 with a
1-LOD interval of 20 cM between markers D1Mit13 and
D1Rat76. This locus overlaps with Iddm9/10 previously
identiﬁed in crosses between the BB/OK and either DA
or SHR/Mol strains (9). Strikingly, this locus contains
the Ins-2 gene (202.93 Mb), one of two homologues of
the human INS gene that is associated with human type
1 diabetes with the second highest odds ratio (31,32)
(Table 2).
Two other resistance loci on chromosomes 3 and 12 are
novel. Although the former showed signiﬁcant linkage
when diabetic F2 animals were analyzed, linkage was only
suggestive (LOD  2.68; Iddm27) when the whole cohort
was included, with a 1-LOD interval spanning 19 cM
between D3Rat24 and D3Rat114. The latter locus is the
second most signiﬁcant resistance locus (LOD  3.82;
Iddm30) and has a 1-LOD interval of 24 cM between
markers D12Got11 and D12Rat15. C12orf30, one of the
loci associated with human type 1 diabetes (36.23 Mb), is
located within this locus—though outside the 1-LOD inter-
val (18) (Table 2).
Linkage analysis of insulitis. Two subphenotypes of
insulitis were assessed in the diabetic and nondiabetic F2
progeny: the intensity of islet inﬁltration by inﬂammatory
cells and the level of islet integrity. The distribution of
these two subphenotypes was very different between the
diabetic and nondiabetic F2 animals (Fig. 3). Speciﬁcally,
while the vast majority of nondiabetic animals had intact
islets and no cellular inﬁltration, all diabetic animals
exhibited a mixture of islet atrophy and islet inﬂammation.
Importantly, in both cohorts of diabetic and nondiabetic
animals, there was a strong correlation (P  0.0001,
Spearman’s rank correlation) between islet integrity and
inﬂammation. However, while this correlation was nega-
tive in the nondiabetic F2 animals, where islets exhibiting
some degree of inﬂammation tended to have decreased
integrity, it was positive in diabetic F2 animals. This
observation in diabetic F2 animals most likely reﬂects the
progressive disappearance of inﬂammatory cells from
islets as their -cells are destroyed (Fig. 3). Of note,
though comparison of pancreatic lesions in nondiabetic
male and female F2 animals revealed signiﬁcantly (P 
0.0013) more severe islet atrophy in females (data not
shown), no evidence for signiﬁcant QTL  sex interaction
was found for either insulitis trait.
It is important to note that while the diabetic F2 animals
were genotyped across the whole genome, nondiabetic
animals were only genotyped at regions that at some point
during the study showed evidence for linkage to type 1
diabetes. Consequently, nondiabetic animals only contrib-
uted to linkage analysis at these regions. In most cases, the
loci controlling the two insulitis subphenotypes overlap
with those described above that inﬂuence type 1 diabetes
susceptibility.
Cellular inﬁltration. Three of the loci found to signiﬁ-
cantly inﬂuence cellular inﬁltration of pancreatic islets
overlap with type 1 diabetes loci on chromosomes 6
(LOD  6.78), 12 (LOD  6.57), and 14 (LOD  3.79), as
illustrated in supplementary Figs. 3B,5 C, and 3C, respec-
tively, while one novel locus on chromosome 8 (LOD 
2.63) is unlinked to type 1 diabetes (Table 1) and, impor-
tantly, regulates cellular inﬁltration of islets in diabetic F2
animals only (supplementary Table 1, Fig. 2, and supple-
mentary Fig. 6). At the peak of those loci regulating both
cellular inﬁltration and type 1 diabetes, the BBDP allele
has consistent susceptibility (chromosomes 6 and 14) or
resistance (chromosome 12) effects on the two traits
(Table 1). At the novel chromosome 8 locus, found in
diabetic F2 animals only, the BBDP allele is associated
with a decreased cellular inﬁltration (Table 1), possibly
due to its concomitant deleterious effect on islet integ-
rity hence on the disappearance of -cells (see below
and Fig. 3E).
Islet integrity. The vast majority of the loci linked to islet
integrity are also linked to type 1 diabetes in this cross
(Fig. 2 and Table 1). The seven loci showing signiﬁcant
linkage (supplementary Figs. 3–6) map to chromosomes 1
(LOD  4.19), 6 (LOD  4.55 and 7.54 for the centromeric
and telomeric loci, respectively), 8 (LOD  3.75), 12
(LOD  4.56), 14 (LOD  3.74), and 17 (LOD  3.28).
Other loci on chromosomes 2, 3, and 16 are suggestively
linked to islet integrity in this cross (Table 1 and Fig. 2).
Again, at all of these loci, the protective or deleterious
effect of the BBDP allele was consistent with its effect on
TYPE 1 DIABETES IN THE BB RAT
1010 DIABETES, VOL. 58, APRIL 2009T
A
B
L
E
1
P
e
a
k
m
a
r
k
e
r
s
a
t
e
a
c
h
l
o
c
u
s
l
i
n
k
e
d
t
o
t
y
p
e
1
d
i
a
b
e
t
e
s
a
n
d
r
e
l
a
t
e
d
t
r
a
i
t
s
C
h
r
o
m
o
s
o
m
e
M
a
r
k
e
r
P
o
s
i
t
i
o
n
T
r
a
i
t
D
a
t
a
s
e
t
D
/
N
D
/
W
G
e
n
o
t
y
p
e
a
n
d
p
h
e
n
o
t
y
p
e
d
i
s
t
r
i
b
u
t
i
o
n
L
O
D
s
c
o
r
e
R
2
A
A
A
B
B
B
c
M
M
b
n
/
D
:
N
D
M
e
a
n

S
D
%
t
y
p
e
1
d
i
a
b
e
t
e
s
n
/
D
:
N
D
M
e
a
n

S
D
%
t
y
p
e
1
d
i
a
b
e
t
e
s
n
/
D
:
N
D
M
e
a
n

S
D
%
t
y
p
e
1
d
i
a
b
e
t
e
s
1
D
1
R
a
t
1
5
9
1
2
3
.
8
1
9
8
.
8
C
e
l
l
u
l
a
r
i
n
ﬁ
l
t
r
a
t
i
o
n
D
3
5
1
.
3
0

0
.
6
3
5
5
1
.
4
5

0
.
8
5
1
4
1
.
8
1

1
.
0
0
2
.
9
3
1
2
.
7
3
1
D
1
R
a
t
1
5
9
1
2
3
.
8
1
9
8
.
8
I
s
l
e
t
i
n
t
e
g
r
i
t
y
D
3
5
1
.
2
1

0
.
8
3
5
5
1
.
5
1

0
.
8
8
1
4
1
.
7
8

0
.
8
1
2
.
3
4
1
0
.
2
8
1
D
1
W
o
x
2
3
1
3
2
.
4
2
1
2
.
1
I
s
l
e
t
i
n
t
e
g
r
i
t
y
W
9
8
2
.
4
4

0
.
8
9
2
1
9
2
.
5
7

0
.
7
8
1
2
8
2
.
8
2

0
.
5
0
4
.
1
9
3
.
6
6
1
D
1
W
o
x
2
3
1
3
2
.
4
2
1
2
.
1
T
y
p
e
1
d
i
a
b
e
t
e
s
W
3
6
:
9
8
2
6
.
9
%
5
6
:
2
1
9
2
0
.
4
%
1
1
:
1
2
8
7
.
9
%
4
.
1
8
3
.
7
3
1
D
1
R
a
t
7
6
1
5
3
.
3
2
3
0
.
4
C
e
l
l
u
l
a
r
i
n
ﬁ
l
t
r
a
t
i
o
n
N
D
1
0
1
0
.
4
1

0
.
6
4
2
2
1
0
.
5
8

0
.
7
6
1
2
3
0
.
5
6

0
.
7
4
2
.
6
1
2
.
7
8
2
D
2
A
r
b
7
4
1
.
7
5
7
.
2
I
s
l
e
t
i
n
t
e
g
r
i
t
y
D
2
1
1
.
3
0

0
.
5
0
4
9
1
.
1
0

0
.
4
3
2
8
0
.
8
4

0
.
4
1
2
.
8
2
1
3
.
2
0
2
D
2
R
a
t
1
8
0
7
3
.
3
1
2
1
.
2
A
O
O
D
1
9
1
2
6

1
9
.
9
2
4
1
2
1

2
2
.
6
3
1
1
0
7

2
1
.
1
2
.
3
6
1
0
.
3
7
2
D
2
R
a
t
1
8
0
7
3
.
3
1
2
1
.
2
I
s
l
e
t
i
n
t
e
g
r
i
t
y
W
1
2
9
2
.
7
5

0
.
5
9
2
1
3
2
.
5
9

0
.
7
7
1
0
4
2
.
4
7

0
.
8
8
2
.
5
5
2
.
6
6
2
D
2
G
o
t
1
2
1
9
2
.
6
1
9
3
.
8
I
s
l
e
t
i
n
t
e
g
r
i
t
y
W
1
1
9
2
.
7
5

0
.
5
7
2
2
2
2
.
6
1

0
.
7
7
1
0
2
2
.
4
3

0
.
8
7
2
.
7
4
2
.
2
0
2
D
2
A
r
b
1
6
9
4
.
4
1
9
8
.
3
T
y
p
e
1
d
i
a
b
e
t
e
s
W
1
1
:
1
2
1
8
.
3
%
6
1
:
2
2
1
2
1
.
6
%
3
2
:
1
0
1
2
4
.
1
%
2
.
9
0
2
.
3
8
2
D
2
R
a
t
8
8
1
1
6
.
1
2
2
2
.
3
A
O
O
D
1
8
1
2
8

2
1
.
3
5
5
1
1
9

2
3
.
0
3
1
1
1
0

2
0
.
8
2
.
9
8
1
3
.
9
2
2
D
2
R
a
t
8
8
1
1
6
.
1
2
2
2
.
3
C
e
l
l
u
l
a
r
i
n
ﬁ
l
t
r
a
t
i
o
n
N
D
1
1
9
0
.
5
8

0
.
7
4
2
2
3
0
.
5
1

0
.
7
4
1
0
4
0
.
5
4

0
.
7
0
1
.
8
8
2
.
1
1
3
D
3
R
a
t
7
1
1
2
.
5
1
4
5
.
6
I
s
l
e
t
i
n
t
e
g
r
i
t
y
W
1
5
8
2
.
4
2

0
.
8
9
2
5
9
2
.
6
6

0
.
6
9
1
2
4
2
.
6
9

0
.
7
2
2
.
8
9
2
.
4
4
3
D
3
R
a
t
7
1
1
2
.
5
1
4
5
.
6
T
y
p
e
1
d
i
a
b
e
t
e
s
W
4
5
:
1
1
3
2
8
.
5
%
4
1
:
2
1
8
1
5
.
8
%
1
8
:
1
0
6
1
4
.
5
%
2
.
6
8
2
.
2
1
6
D
6
R
a
t
8
8
7
0
.
3
1
0
0
.
2
T
y
p
e
1
d
i
a
b
e
t
e
s
W
1
3
:
1
1
7
1
0
%
4
5
:
2
1
7
1
7
.
2
%
4
5
:
1
0
2
3
0
.
6
%
5
.
2
1
4
.
4
8
6
D
6
R
a
t
8
1
7
6
.
3
1
1
2
.
0
I
s
l
e
t
i
n
t
e
g
r
i
t
y
W
1
0
7
2
.
7
8

0
.
5
4
2
3
8
2
.
6
4

0
.
7
2
1
0
0
2
.
3
8

0
.
9
3
4
.
5
5
3
.
9
1
6
D
6
R
a
t
9
4
9
4
.
1
1
3
1
.
5
C
e
l
l
u
l
a
r
i
n
ﬁ
l
t
r
a
t
i
o
n
N
D
1
2
0
0
.
4
2

0
.
6
6
2
2
7
0
.
5
2

0
.
7
7
9
4
0
.
7
1

0
.
7
2
2
.
0
4
2
.
0
8
6
D
6
R
a
t
1
5
2
9
8
.
0
1
4
2
.
5
C
e
l
l
u
l
a
r
i
n
ﬁ
l
t
r
a
t
i
o
n
W
1
1
8
0
.
5
3

0
.
7
5
2
3
6
0
.
6
7

0
.
8
2
9
2
1
.
0
6

0
.
8
8
6
.
7
8
5
.
3
5
6
D
6
R
a
t
1
5
2
9
8
.
0
1
4
2
.
5
I
s
l
e
t
i
n
t
e
g
r
i
t
y
W
1
1
8
2
.
8
1

0
.
5
2
2
3
6
2
.
6
6

0
.
7
2
9
2
2
.
3
0

0
.
9
4
7
.
5
4
5
.
9
3
6
D
6
R
a
t
1
9
8
.
4
1
4
4
.
2
T
y
p
e
1
d
i
a
b
e
t
e
s
W
8
:
1
2
0
6
.
3
%
5
0
:
2
3
4
1
7
.
6
%
4
6
:
9
2
3
3
.
3
%
7
.
6
6
6
.
3
2
7
D
7
R
a
t
3
0
2
0
.
7
3
0
.
3
C
e
l
l
u
l
a
r
i
n
ﬁ
l
t
r
a
t
i
o
n
D
2
6
2
.
0
6

0
.
8
3
5
6
1
.
5
6

0
.
6
2
1
5
1
.
3
6

0
.
3
1
3
.
0
0
1
6
.
7
8
7
D
7
W
o
x
4
8
9
7
.
5
1
2
9
.
5
A
O
O
D
3
0
1
2
1

2
2
.
9
5
2
1
2
1

2
1
.
8
2
2
1
0
3

2
0
.
0
2
.
7
1
1
5
.
3
7
8
D
8
R
a
t
2
0
6
9
.
2
9
4
.
9
I
s
l
e
t
i
n
t
e
g
r
i
t
y
D
2
3
1
.
2
4

0
.
3
8
4
4
1
.
1
5

0
.
4
8
3
1
0
.
8
3

0
.
4
2
3
.
7
5
1
8
.
2
3
8
D
8
R
a
t
6
5
9
1
.
3
1
0
9
.
9
C
e
l
l
u
l
a
r
i
n
ﬁ
l
t
r
a
t
i
o
n
D
1
8
2
.
1
2

0
.
7
2
5
1
1
.
6
6

0
.
6
4
2
7
1
.
4
2

0
.
6
3
2
.
6
3
1
2
.
5
4
1
2
D
1
2
R
a
t
2
8
2
0
.
3
1
6
.
3
C
e
l
l
u
l
a
r
i
n
ﬁ
l
t
r
a
t
i
o
n
N
D
9
6
0
.
7
8

0
.
8
6
2
2
3
0
.
5
3

0
.
7
2
1
2
2
0
.
3
7

0
.
5
9
3
.
6
5
3
.
6
9
1
2
D
1
2
R
a
t
2
8
2
0
.
3
1
6
.
3
C
e
l
l
u
l
a
r
i
n
ﬁ
l
t
r
a
t
i
o
n
W
9
6
1
.
0
3

0
.
9
4
2
2
3
0
.
7
3

0
.
8
1
1
2
2
0
.
4
7

0
.
7
1
6
.
5
7
5
.
1
9
1
2
D
1
2
R
a
t
2
8
2
0
.
3
1
6
.
3
I
s
l
e
t
i
n
t
e
g
r
i
t
y
W
9
6
2
.
4
1

0
.
8
7
2
2
3
2
.
5
9

0
.
7
7
1
2
2
2
.
8
1

0
.
5
4
4
.
5
6
3
.
8
7
1
2
D
1
2
R
a
t
2
8
2
0
.
3
1
6
.
3
T
y
p
e
1
d
i
a
b
e
t
e
s
W
3
6
:
9
6
2
7
.
3
%
5
8
:
2
2
3
2
0
.
6
%
1
0
:
1
2
2
7
.
6
%
3
.
8
2
3
.
1
4
1
4
D
1
4
R
a
t
1
3
.
4
4
.
9
I
s
l
e
t
i
n
t
e
g
r
i
t
y
W
1
2
7
2
.
7
5

0
.
6
2
2
2
7
2
.
6
2

0
.
7
6
9
2
2
.
4
0

0
.
8
6
3
.
7
4
3
.
3
0
1
4
D
1
4
R
a
t
1
3
.
4
4
.
9
T
y
p
e
1
d
i
a
b
e
t
e
s
W
1
4
:
1
2
7
9
.
9
%
5
1
:
2
2
7
1
8
.
3
%
3
9
:
9
2
2
9
.
8
%
4
.
7
0
4
.
1
3
1
4
D
1
4
R
a
t
4
2
8
.
8
1
4
.
3
C
e
l
l
u
l
a
r
i
n
ﬁ
l
t
r
a
t
i
o
n
W
1
1
4
0
.
6
0

0
.
7
8
2
2
5
0
.
6
8

0
.
8
3
8
6
0
.
9
9

0
.
9
2
3
.
7
9
3
.
0
3
1
7
D
1
7
R
a
t
1
1
1
9
.
9
3
0
.
9
I
s
l
e
t
i
n
t
e
g
r
i
t
y
W
1
1
8
2
.
7
0

0
.
6
6
2
2
9
2
.
6
3

0
.
7
4
9
3
2
.
4
3

0
.
8
9
3
.
2
8
3
.
2
8
1
7
D
1
7
R
a
t
1
1
1
9
.
9
3
0
.
9
T
y
p
e
1
d
i
a
b
e
t
e
s
W
2
0
:
1
3
8
1
4
.
5
%
5
1
:
2
8
0
1
8
.
2
%
3
3
:
9
3
2
6
.
2
%
1
.
9
8
1
.
9
5
1
8
D
1
8
R
a
t
1
1
6
1
6
.
3
4
0
.
6
A
O
O
D
3
0
1
0
7

1
7
.
3
5
0
1
2
0

2
3
.
0
1
8
1
2
8

2
4
.
0
2
.
7
9
1
2
.
8
5
F
o
r
e
a
c
h
m
i
c
r
o
s
a
t
e
l
l
i
t
e
m
a
r
k
e
r
,
b
o
t
h
t
h
e
g
e
n
e
t
i
c
(
c
M
)
a
n
d
p
h
y
s
i
c
a
l
p
o
s
i
t
i
o
n
s
(
M
b
)
a
r
e
s
h
o
w
n
,
a
n
d
t
h
e
t
r
a
i
t
t
o
w
h
i
c
h
l
i
n
k
a
g
e
w
a
s
f
o
u
n
d
i
s
i
n
d
i
c
a
t
e
d
.
T
h
r
e
e
d
i
f
f
e
r
e
n
t
d
a
t
a
s
e
t
s
w
e
r
e
u
s
e
d
:
D
,
d
i
a
b
e
t
i
c
a
n
i
m
a
l
s
o
n
l
y
;
N
D
,
n
o
n
d
i
a
b
e
t
i
c
a
n
i
m
a
l
s
o
n
l
y
;
W
,
w
h
o
l
e
c
o
h
o
r
t
.
T
h
e
d
i
s
t
r
i
b
u
t
i
o
n
o
f
g
e
n
o
t
y
p
e
s
a
n
d
p
h
e
n
o
t
y
p
e
s
f
o
r
e
a
c
h
o
f
t
h
e
s
e
d
a
t
a
s
e
t
s
i
s
i
n
d
i
c
a
t
e
d
a
s
f
o
l
l
o
w
s
.
F
o
r
t
h
e
g
e
n
o
t
y
p
e
s
:
A
A
,
A
C
I
.
B
B
1
u
.
l
y
p
h
o
m
o
z
y
g
o
u
s
,
A
B
,
h
e
t
e
r
o
z
y
g
o
u
s
,
a
n
d
B
B
,
B
B
D
P
h
o
m
o
z
y
g
o
u
s
.
F
o
r
e
a
c
h
g
e
n
o
t
y
p
e
,
t
h
e
ﬁ
r
s
t
c
o
l
u
m
n
i
n
d
i
c
a
t
e
s
t
h
e
n
u
m
b
e
r
o
f
a
n
i
m
a
l
s
,
e
x
c
e
p
t
f
o
r
t
h
e
t
y
p
e
1
d
i
a
b
e
t
e
s
t
r
a
i
t
f
o
r
w
h
i
c
h
t
h
e
n
u
m
b
e
r
o
f
d
i
a
b
e
t
i
c
a
n
d
n
o
n
d
i
a
b
e
t
i
c
(
D
:
N
D
)
a
n
i
m
a
l
s
i
s
g
i
v
e
n
.
T
h
e
s
e
c
o
n
d
c
o
l
u
m
n
s
h
o
w
s
t
h
e
m
e
a
n
v
a
l
u
e
f
o
r
e
a
c
h
t
r
a
i
t

S
D
,
e
x
c
e
p
t
f
o
r
t
y
p
e
1
d
i
a
b
e
t
e
s
,
f
o
r
w
h
i
c
h
t
h
e
c
u
m
u
l
a
t
i
v
e
i
n
c
i
d
e
n
c
e
i
s
g
i
v
e
n
a
s
a
p
e
r
c
e
n
t
a
g
e
.
T
h
e
ﬁ
n
a
l
t
w
o
c
o
l
u
m
n
s
s
h
o
w
t
h
e
L
O
D
s
c
o
r
e
r
e
a
c
h
e
d
a
n
d
t
h
e
p
r
o
p
o
r
t
i
o
n
o
f
t
r
a
i
t
v
a
r
i
a
n
c
e
(
R
2
)
a
c
c
o
u
n
t
e
d
f
o
r
b
y
e
a
c
h
l
o
c
u
s
.
R.H. WALLIS AND ASSOCIATES
DIABETES, VOL. 58, APRIL 2009 1011T
A
B
L
E
2
M
u
r
i
n
e
a
n
d
h
u
m
a
n
c
h
r
o
m
o
s
o
m
a
l
r
e
g
i
o
n
s
s
y
n
t
e
n
i
c
t
o
I
d
d
m
l
o
c
i
R
a
t
M
o
u
s
e
H
u
m
a
n
C
a
n
d
i
d
a
t
e
g
e
n
e
s
C
h
r
o
m
o
s
o
m
e
M
a
r
k
e
r
(
1
-
L
O
D
i
n
t
e
r
v
a
l
)
P
o
s
i
t
i
o
n
(
M
b
)
T
r
a
i
t
I
d
d
m
l
o
c
u
s
C
h
r
o
m
o
s
o
m
e
P
o
s
i
t
i
o
n
(
M
b
)
I
d
d
l
o
c
u
s
(
M
b
)
C
h
r
o
m
o
s
o
m
e
P
o
s
i
t
i
o
n
(
M
b
)
I
D
D
M
l
o
c
u
s
/
G
W
A
(
M
b
)
1
D
1
M
i
t
1
3
D
1
R
a
t
7
6
1
8
6
.
5
2
3
0
.
4
T
y
p
e
1
d
i
a
b
e
t
e
s
/
i
s
l
e
t
i
n
t
e
g
r
i
t
y
I
d
d
m
2
5
7
1
1
4
.
7
–
1
3
2
.
6
I
d
d
2
7
(
8
6
.
5
–
1
2
7
.
0
)
1
6
3
0
.
3
–
3
1
.
4
1
0
1
2
4
.
2
–
1
3
5
.
2
1
9
3
.
0
–
2
4
.
8
1
1
6
.
1
–
2
.
4
G
W
A
S
N
P
:
r
s
6
8
9
I
N
S
/
I
G
F
2
I
D
D
M
2
(
2
.
0
–
2
.
3
)
1
1
5
8
.
2
–
7
0
.
8
I
D
D
M
4
(
5
9
.
2
–
6
8
.
5
)
L
R
P
5
/
G
A
L
/
F
A
D
D
9
6
9
.
3
–
7
9
.
4
2
D
2
R
a
t
7
5
D
2
M
i
t
8
7
9
.
8
1
4
8
.
8
A
O
O
/
i
s
l
e
t
i
n
t
e
g
r
i
t
y
I
d
d
m
3
2
1
5
3
1
.
3
–
3
2
.
2
5
9
.
7
–
1
0
.
7
3
5
.
6
–
1
4
.
9
8
6
7
.
3
–
8
6
.
6
3
1
5
0
.
0
–
1
8
1
.
0
I
D
D
M
9
(
1
3
8
.
8
–
1
7
0
.
6
)
C
P
3
1
9
.
4
–
5
9
.
4
I
d
d
3
(
3
6
.
6
–
3
7
.
3
)
4
1
2
3
.
0
–
1
3
0
.
2
G
W
A
S
N
P
:
r
s
3
1
3
6
5
3
4
A
D
A
D
1
,
I
L
2
,
I
L
2
1
,
K
I
A
A
1
1
0
9
1
3
3
5
.
2
–
3
7
.
1
3
1
4
8
.
5
–
1
5
0
.
7
I
D
D
M
9
(
1
3
8
.
8
–
1
7
0
.
6
)
2
D
2
R
a
t
4
4
D
2
R
a
t
8
8
1
8
1
.
7
2
2
2
.
3
T
y
p
e
1
d
i
a
b
e
t
e
s
/
i
s
l
e
t
i
n
t
e
g
r
i
t
y
I
d
d
m
2
6
3
9
0
.
2
–
1
4
7
.
2
I
d
d
1
0
(
1
0
0
.
1
–
1
0
1
.
0
)
1
1
4
3
.
9
–
1
5
1
.
4
I
d
d
1
8
.
2
(
1
0
1
.
0
–
1
0
8
.
2
)
1
9
4
.
1
–
1
2
0
.
2
G
W
A
S
N
P
:
r
s
6
6
7
9
6
7
7
P
T
P
N
2
2
2
D
2
R
a
t
8
2
2
1
4
.
6
A
O
O
I
d
d
m
3
3
I
d
d
1
8
.
1
(
1
0
9
.
9
–
1
0
9
.
6
)
4
1
0
0
.
2
–
1
2
0
.
6
N
F
K
B
1
/
F
A
B
P
2
D
2
R
a
t
6
9
2
4
7
.
3
1
8
2
.
0
–
8
9
.
0
3
D
3
R
a
t
2
4
9
6
.
5
T
y
p
e
1
d
i
a
b
e
t
e
s
I
d
d
m
2
7
2
1
1
2
.
4
–
1
5
8
.
2
I
d
d
1
3
(
1
1
4
.
1
–
1
5
8
.
3
)
1
5
3
0
.
7
–
4
7
.
2
B
2
m
D
3
R
a
t
1
1
4
1
4
9
.
5
2
9
5
.
4
–
1
1
3
.
3
I
L
1
A
/
I
L
1
B
2
0
0
.
3
–
3
6
.
2
6
D
6
R
a
t
2
3
D
6
G
o
t
1
6
9
7
4
.
4
1
2
3
.
6
T
y
p
e
1
d
i
a
b
e
t
e
s
/
i
s
l
e
t
i
n
t
e
g
r
i
t
y
I
d
d
m
2
8
1
2
5
0
.
6
–
9
3
.
3
1
4
3
4
.
8
–
8
8
.
1
I
D
D
M
1
1
(
8
5
.
0
–
9
2
.
4
)
P
Y
G
L
/
S
E
L
1
6
D
6
M
g
h
3
D
6
G
o
t
1
6
7
1
2
7
.
7
1
4
6
.
7
T
y
p
e
1
d
i
a
b
e
t
e
s
/
c
e
l
l
u
l
a
r
i
n
ﬁ
l
t
r
a
t
i
o
n
/
i
s
l
e
t
i
n
t
e
g
r
i
t
y
I
d
d
m
2
9
1
2
9
8
.
3
–
1
1
1
.
5
1
4
9
3
.
8
–
1
0
5
.
0
R
A
G
E
7
1
2
6
.
8
–
1
5
8
.
3
7
D
7
R
a
t
2
1
9
6
.
5
A
O
O
I
d
d
m
3
4
1
5
6
2
.
2
–
9
9
.
3
8
1
2
8
.
8
–
1
4
6
.
0
D
7
R
a
t
2
1
3
7
.
7
2
2
3
5
.
0
–
4
9
.
5
G
W
A
S
N
P
:
r
s
2
2
9
5
4
1
C
1
Q
T
N
F
6
,
S
S
T
R
3
1
2
3
8
.
2
–
4
7
.
7
V
D
R
1
2
D
1
2
G
o
t
1
1
D
1
2
R
a
t
1
5
8
.
9
2
9
.
4
T
y
p
e
1
d
i
a
b
e
t
e
s
/
c
e
l
l
u
l
a
r
i
n
ﬁ
l
t
r
a
t
i
o
n
/
i
s
l
e
t
i
n
t
e
g
r
i
t
y
I
d
d
m
3
0
5
1
2
6
.
5
–
1
4
3
.
9
7
0
.
7
–
5
9
.
8
N
U
D
T
1
7
5
5
.
9
–
1
0
1
.
5
P
O
N
2
1
2
1
2
9
.
9
–
1
3
0
.
8
G
W
A
S
N
P
:
r
s
3
1
8
4
5
0
4
C
1
2
o
r
f
3
0
,
P
T
P
N
1
1
TYPE 1 DIABETES IN THE BB RAT
1012 DIABETES, VOL. 58, APRIL 2009T
A
B
L
E
2
C
o
n
t
i
n
u
e
d
R
a
t
M
o
u
s
e
H
u
m
a
n
C
a
n
d
i
d
a
t
e
g
e
n
e
s
C
h
r
o
m
o
s
o
m
e
M
a
r
k
e
r
(
1
-
L
O
D
i
n
t
e
r
v
a
l
)
P
o
s
i
t
i
o
n
(
M
b
)
T
r
a
i
t
I
d
d
m
l
o
c
u
s
C
h
r
o
m
o
s
o
m
e
P
o
s
i
t
i
o
n
(
M
b
)
I
d
d
l
o
c
u
s
(
M
b
)
C
h
r
o
m
o
s
o
m
e
P
o
s
i
t
i
o
n
(
M
b
)
I
D
D
M
l
o
c
u
s
/
G
W
A
(
M
b
)
1
4
D
1
4
R
a
t
1
D
1
4
M
i
t
6
4
.
9
1
9
.
8
T
y
p
e
1
d
i
a
b
e
t
e
s
/
c
e
l
l
u
l
a
r
i
n
ﬁ
l
t
r
a
t
i
o
n
/
i
s
l
e
t
i
n
t
e
g
r
i
t
y
I
d
d
m
3
1
5
8
9
.
3
–
1
0
1
.
8
4
7
4
.
6
–
8
9
.
3
1
9
.
8
1
7
D
1
7
R
a
t
6
D
1
7
R
a
t
7
8
1
6
.
1
4
7
.
6
T
y
p
e
1
d
i
a
b
e
t
e
s
/
i
s
l
e
t
i
n
t
e
g
r
i
t
y
I
d
d
m
3
6
1
3
2
6
.
4
–
5
3
.
7
I
d
d
1
4
(
2
5
.
4
–
1
2
0
.
3
)
5
1
7
4
.
1
–
1
7
5
.
2
9
8
9
.
2
–
9
3
.
0
6
2
.
7
–
1
6
.
3
6
2
2
.
4
–
2
4
.
5
1
8
D
1
8
R
a
t
1
0
9
4
.
3
A
O
O
I
d
d
m
3
5
1
8
1
5
.
8
–
6
6
.
5
I
d
d
2
1
.
2
(
6
4
.
6
–
7
4
.
6
)
1
8
2
2
.
7
–
3
9
.
1
D
1
8
A
r
b
6
6
2
.
7
5
1
1
0
.
6
–
1
2
7
.
6
5
1
3
7
.
8
–
1
5
0
.
1
1
8
5
2
.
4
–
5
5
.
2
I
D
D
M
6
(
3
4
.
1
–
6
1
.
2
)
S
L
C
1
4
A
1
I
n
t
h
e
r
a
t
,
t
h
e
c
h
r
o
m
o
s
o
m
e
n
u
m
b
e
r
,
t
h
e
m
a
r
k
e
r
s
ﬂ
a
n
k
i
n
g
t
h
e
1
-
L
O
D
i
n
t
e
r
v
a
l
,
t
h
e
i
r
p
h
y
s
i
c
a
l
p
o
s
i
t
i
o
n
i
n
M
b
,
a
n
d
t
h
e
t
r
a
i
t
(
s
)
t
o
w
h
i
c
h
l
i
n
k
a
g
e
w
a
s
f
o
u
n
d
a
r
e
g
i
v
e
n
f
o
r
e
a
c
h
I
d
d
m
l
o
c
u
s
.
F
o
r
m
u
r
i
n
e
r
e
g
i
o
n
s
s
y
n
t
e
n
i
c
t
o
e
a
c
h
I
d
d
m
l
o
c
u
s
,
t
h
e
c
h
r
o
m
o
s
o
m
e
n
u
m
b
e
r
,
t
h
e
l
i
m
i
t
s
o
f
e
a
c
h
c
h
r
o
m
o
s
o
m
a
l
i
n
t
e
r
v
a
l
(
i
n
M
b
)
,
a
n
d
,
w
h
e
n
p
r
e
s
e
n
t
,
t
h
e
I
d
d
l
o
c
i
s
i
t
u
a
t
e
d
w
i
t
h
i
n
t
h
e
s
y
n
t
e
n
i
c
i
n
t
e
r
v
a
l
s
a
r
e
i
n
d
i
c
a
t
e
d
t
o
g
e
t
h
e
r
w
i
t
h
t
h
e
i
r
p
h
y
s
i
c
a
l
l
o
c
a
t
i
o
n
.
F
o
r
h
u
m
a
n
r
e
g
i
o
n
s
s
y
n
t
e
n
i
c
t
o
e
a
c
h
I
d
d
m
l
o
c
u
s
,
t
h
e
c
h
r
o
m
o
s
o
m
e
n
u
m
b
e
r
,
t
h
e
l
i
m
i
t
s
o
f
e
a
c
h
c
h
r
o
m
o
s
o
m
a
l
i
n
t
e
r
v
a
l
(
i
n
M
b
)
,
a
n
d
,
w
h
e
n
p
r
e
s
e
n
t
,
t
h
e
I
D
D
M
l
o
c
i
s
i
t
u
a
t
e
d
w
i
t
h
i
n
t
h
e
s
y
n
t
e
n
i
c
i
n
t
e
r
v
a
l
s
a
r
e
i
n
d
i
c
a
t
e
d
t
o
g
e
t
h
e
r
w
i
t
h
t
h
e
i
r
p
h
y
s
i
c
a
l
l
o
c
a
t
i
o
n
.
T
h
e
S
N
P
s
r
e
c
e
n
t
l
y
f
o
u
n
d
t
o
r
e
a
c
h
s
i
g
n
i
ﬁ
c
a
n
t
,
g
e
n
o
m
e
-
w
i
d
e
a
s
s
o
c
i
a
t
i
o
n
(
G
W
A
)
w
i
t
h
t
y
p
e
1
d
i
a
b
e
t
e
s
a
r
e
a
l
s
o
i
n
d
i
c
a
t
e
d
.
T
h
e
l
a
s
t
c
o
l
u
m
n
i
n
d
i
c
a
t
e
s
g
e
n
e
s
i
n
c
l
o
s
e
l
i
n
k
a
g
e
d
i
s
e
q
u
i
l
i
b
r
i
u
m
w
i
t
h
G
W
A
S
N
P
s
,
a
s
w
e
l
l
a
s
t
h
e
p
o
s
i
t
i
o
n
a
l
c
a
n
d
i
d
a
t
e
g
e
n
e
s
w
i
t
h
i
n
t
h
e
I
d
d
a
n
d
I
D
D
M
l
o
c
i
a
s
l
i
s
t
e
d
i
n
w
w
w
.
t
1
d
b
a
s
e
.
o
r
g
.
R.H. WALLIS AND ASSOCIATES
DIABETES, VOL. 58, APRIL 2009 1013type 1 diabetes, conferring resistance to type 1 diabetes
and relative protection from islet atrophy on chromo-
somes 1, 3, and 12 as opposed to increased susceptibility
to type 1 diabetes and islet atrophy on chromosomes 2, 6,
8, 14, and 17 (Table 1 and supplementary Table 1).
Linkage analysis of AOO of diabetes. Four chromo-
somal regions on chromosomes 2, 7, and 18 were found to
inﬂuence the age at which type 1 diabetes develops in F2
animals (Fig. 2 and supplementary Fig. 7). Both chromo-
some 2 AOO loci (LOD  2.36, Iddm32; and LOD  2.98,
Iddm33 for the centromeric and telomeric loci, respec-
tively) overlap with two suggestive loci controlling islet
integrity (Table 1 and supplementary Table 1). As ex-
pected, based on the deleterious effect of the BBDP alleles
on islet integrity at both loci, these alleles are also
associated with early onset of type 1 diabetes (Table 1).
Importantly, Il-2 and Il-21, which are associated with type
1 diabetes in both humans and NOD mice, are located
within the Iddm32 locus (Table 2) (18,33). The two AOO
loci on chromosomes 7 (LOD  2.71; Iddm34) and 18
(LOD  2.79; Iddm35) did not overlap with any type 1
diabetes or insulitis loci (supplementary Table 1). How-
ever, the former locus contains C1qtnf6, recently found to
be associated with human type 1 diabetes by meta-analysis
of genome-wide association studies (34). While BBDP
homozygosity at the peak of the chromosome 7 locus was
associated with early type 1 diabetes development, at the
peak of the chromosome 18 locus it delayed onset of the
disease (Table 1). Of note, although a type 1 diabetes
chromosome 18 locus overlapping with Iddm35 was iden-
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was not linked to AOO, and the BB/OK allele conferred
increased susceptibility to type 1 diabetes (35).
DISCUSSION
This study has identiﬁed no less than 12 loci designated
Iddm25 to Iddm36, inﬂuencing the diabetogenic process in
a single cross, thus establishing the polygenic basis of the
disease in the BBDP rat. Six of these loci on chromosomes
1, 6 (two loci), 12, 14, and 17 showed signiﬁcant linkage to
type 1 diabetes and/or insulitis, while six on chromosomes
2 (three loci), 3, 7, and 18 reached suggestive linkage to
type 1 diabetes or AOO. The BBDP, KDP, and LEW.1AR1
rat strains spontaneously develop type 1 diabetes, and it
initially appeared that these syndromes had a relatively
simple genetic basis with perhaps few susceptibility genes
(36,37). However, the current study demonstrates that this
does not apply to an intercross between the BBDP and
ACI.BB
1u.lyp strains used here. Strikingly, although the
type 1 diabetes loci mapped here are numerous, together
they only account for 30% of the trait variance observed
in the F2 cohort. From the study of Klaff et al. (8), we
calculated that Iddm1 and -2 jointly contributed 9.4% of the
variance of type 1 diabetes in a cross between the type 1
diabetes–susceptible DRlyp/lyp and type 1 diabetes–resis-
tant F344 strains. Assuming that the contribution of these
two genes to type 1 diabetes variance would be similar in
a cross-intercross between BBDP and noncongenic ACI
rats, our results strongly suggest a genetic complexity for
the BBDP diabetic syndrome that is reminiscent of the
human disease.
Genetic analyses using the BBDP strain previously
performed by others made us aware of the very low
number (1%) of diabetic (hence informative) animals
that could be expected in such a classical F2 cohort.
Therefore, we reasoned that a large “conditioned” F2 cross
with the two major Iddm loci ﬁxed as BBDP would
produce more informative animals. Consequently, several
loci, including some contributing small effects to the
disease, could be mapped. Furthermore, this would allow
us to assess the contribution of all three genotypes to the
diabetogenic process. However, a limitation of using a
conditioned cross is that it could not detect genetic
interaction between Gimap5 or RT1u and any of the other
loci detected in our linkage analysis.
Having found multiple type 1 diabetes loci, the question
follows as to why only three of these on chromosomes 1,
2, and 6 were identiﬁed in previous studies (8,9). The ﬁrst
obvious explanation is the extent of genetic polymorphism
between BB rats and the type 1 diabetes–resistant strains
used. In this regard, using recent information on genome-
wide single nucleotide polymorphisms (SNPs) available
from the rat genome database (http://rgd.mcw.edu/), we
found that the BB genotype differed from the ACI, BN,
F344, SHR, and WF strain genotypes at 30, 53, 27, 36, and
23% of the SNPs, respectively. Since the genetic polymor-
phism distinguishing the ACI from the BB strain is not the
most extensive, it is unlikely to be the main explanation
for the detection of many type 1 diabetes loci in this cross.
Rather, this suggests that the type 1 diabetes–resistant
strains used in previous studies had distinct combinations
of type 1 diabetes resistance and susceptibility alleles
compared with the ACI.BB
1u.lyp strain. In support of this,
the current F2 cohort could not map two type 1 diabetes
loci on chromosomes 4 and 18 that were identiﬁed inde-
pendently using distinct type 1 diabetes–resistant strains,
though these loci could segregate in our cross (9,13).
Further, it is perhaps surprising that the chromosome 2
(Iddm3) locus was previously identiﬁed with a much
higher LOD score in a relatively small backcross using the
type 1 diabetes–resistant F344 strain (8). It is possible that
this high LOD score was due to allelic heterogeneity
resulting in a differential effect depending on the resistant
strain used and/or the close proximity of two susceptibility
loci, only one of which segregates in our cross. This is
supported by the slightly more centromeric (	20 cM)
location of the peak of linkage to type 1 diabetes on
chromosome 2 compared with Iddm3 (8).
A second likely explanation for the detection of multiple
type 1 diabetes loci in this cross is its size and its
“conditioned” nature, both resulting in a number of dia-
betic, hence informative, animals signiﬁcantly larger than
in previous studies (8–11). This size-related increase in the
power of our study may also have beneﬁted from the use
of an intercross as opposed to a backcross, since it
allowed the identiﬁcation of three ACI-susceptible (or
BBDP resistance) loci.
The observation of a higher cumulative incidence of
type 1 diabetes in female F2 animals was unexpected since
contrary to the NOD mouse, the BBDP rat does not exhibit
a sex bias in disease susceptibility. This differential, sex-
related type 1 diabetes risk in the F2 cohort was, however,
minimal, and this could explain our inability to detect loci
responsible for the higher disease incidence in females.
This raises the possibility of an environmental risk factor
for females. Paradoxically, the BBDP susceptibility allele
at the only locus showing interaction with sex (chromo-
some 6) confers higher risk for the disease in males.
A successful approach to map type 1 diabetes loci has
taken advantage of the widespread susceptibility to exper-
imentally induced diabetic syndromes among nonlym-
phopenic, RT1u strains of rats (13–16). Linkage analyses
of crosses between these and RT1u, but type 1 diabetes–
resistant, strains identiﬁed some type 1 diabetes loci
including Iddm14 on chromosome 4 that inﬂuences both
spontaneous and experimentally induced type 1 diabetes
(14,15). Of two other loci on chromosomes 13 and 17
previously shown to control experimentally induced type 1
diabetes, only the latter segregates with spontaneous type
1 diabetes in our cross (13,38). Again, this could reﬂect
genetic polymorphism between the type 1 diabetes–resis-
tant WF and ACI.BB
1u.lyp strains used in these studies.
Alternatively, it could indicate that some of the loci
inﬂuencing spontaneous and experimentally induced
diabetic syndromes (hence, some of the pathogenic mech-
anisms involved in these syndromes) are distinct.
Recent genome-wide association studies have success-
fully identiﬁed multiple novel, small-effect genes associ-
ated with type 1 diabetes in humans (17–19,34). This
identiﬁcation should facilitate our understanding of anti-
pancreatic autoimmunity at the molecular level and, sub-
sequently, the design of therapeutic approaches
interfering with these mechanisms. However, the small
effect of these genes has highlighted the importance of
type 1 diabetes–prone animals sharing disease susceptibil-
ity genes or signaling pathways with their human counter-
parts. Speciﬁcally, they could identify additional genetic
risk factors, reveal pathways of previously unknown rele-
vance to the disease, and provide insights into pathogenic
mechanisms controlled by shared susceptibility genes.
The relevance of type 1 diabetes–prone animals to the
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which shares several type 1 diabetes genes and signaling
pathways with type 1 diabetes in humans (33,39,40).
Similarly, the presence of ﬁve genes associated with the
human disease within the Iddm loci identiﬁed in this cross
(Table 2) may facilitate a better understanding of their
contribution to antipancreatic autoimmunity.
Another contribution of experimental models is that
they are accessible to the dissection of disease-related
subphenotypes that are difﬁcult to assess in humans. For
example, the linkage analysis of insulitis subphenotypes
leads to both expected and unexpected results. It is
generally accepted that the outcome of chronic islet
inﬂammation is the destruction of -cells and the subse-
quent development of type 1 diabetes. It is therefore not
surprising that insulitis and type 1 diabetes loci overlap
and that genotypes increasing type 1 diabetes susceptibil-
ity are associated with both intense inﬂammatory inﬁl-
trates in islets and severe islet atrophy (e.g., chromosomes
6 [telomere], 12, and 14 [Table 1]). More surprising is the
observation that some type 1 diabetes loci (e.g., on chro-
mosomes 1, 2, 6 [centromere], and 17) inﬂuence islet
integrity but do not seem to control islet inﬁltration by
immune cells. At the moment, we can speculate that these
loci may control very early steps of the autoimmune
response (e.g., they may inﬂuence the immunogenicity of
-cells). Alternatively, they may regulate an immune mech-
anism that destroys islets independently of the intensity of
the local cellular inﬂammation or the intrinsic ability of
-cells to succumb to the inﬂammatory response.
The incidence of type 1 diabetes is increasing in the
Western world, most rapidly in individuals with onset
before the age of 5 years (41). Importantly, early-onset
type 1 diabetes is associated with an aggressive course
characterized by rapid disappearance of residual -cell
function and a higher risk for preclinical (as assessed by
autoantibodies) and overt disease in siblings and parents
(42,43). There is strong evidence that AOO is under genetic
control (44). Some of the genes associated with AOO have
been identiﬁed in humans, which are all MHC class I and
II genes (17,42,45–47). However, genome-wide association
studies have not identiﬁed novel AOO genes, possibly due
to the fact that many cohorts restricted inclusion to
pediatric onset (18,19,48). Our study identiﬁes four loci
that appear to inﬂuence AOO (though unlinked to type 1
diabetes itself) suggesting that some of these allelic vari-
ations may act upstream of those affecting insulitis and
type 1 diabetes susceptibility, possibly at the level of the
differentiation of the target tissue and/or components of
the immune system.
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